Published date: 29 February 2024

Awarded contract - This means that the contract has been awarded to a supplier.


Closing: 24 November 2023, 12pm

Contract summary

Industry

  • Health services - 85100000

Location of contract

England

Value of contract

£1,397,592 to £2,100,000

Procurement reference

CF-2213500D0O000000rwimUAA

Published date

29 February 2024

Closing date

24 November 2023

Closing time

12pm

Contract start date

12 February 2024

Contract end date

31 March 2026

Contract type

Service contract

Procedure type

Open procedure (above threshold)

Any interested supplier may submit a tender in response to an opportunity notice.

This procedure can be used for procurements above the relevant contract value threshold.

Contract is suitable for SMEs?

Yes

Contract is suitable for VCSEs?

No

Description

The CVLP is a strategic priority and collaboration between NHS England, the Department of Health and Social Care (DHSC), the Office for Life Sciences (OLS), the National Institute of Health Research (NIHR) and Genomics England (GEL), with the aim to facilitate access to personalised cancer vaccine research trials. The project was jointly announced in July 2023 with the Secretary of State and in partnership with the Prime Minister. See link (https://www.gov.uk/government/news/major-agreement-to-deliver-new-cancer-vaccine-trials#:~:text=It will work by creating,become part of standard care)

Through the CVLP platform, cancer patients from across a network of up to 140 NHS cancer care providers will be asked to consent to be put forward for clinical trials. Their surplus tissue samples, obtained through standard of care pathways, will be used to assess their eligibility. The detail of any available trials will be shared with the participant and their treating clinical team to see if the patient wishes to take part, and if so, the patient will travel to the nearest trial site to access the clinical trial.


The CVLP is a feasibility study, facilitating access to personalised treatment cancer trials, for example cancer vaccines. Patients will be identified across a network of up to 140 NHS cancer care providers. Patients in the CVLP will be asked to consent for analysis of their tumour material, peripheral blood (if trial requires), and clinical data to establish whether they might be suitable for current or future cancer vaccine trials. The detail of any available trials will be shared with the participant and their treating clinical team, to see if they would consider taking part in the trial(s) for which they are eligible.

More information

Previous notice about this procurement

Cancer Vaccine Launchpad (CVLP)

  • Awarded contract
  • Published 29 February 2024

Attachments

Award information

Awarded date

12 February 2024

Contract start date

12 February 2024

Contract end date

31 March 2026

Total value of contract

£1,397,592

This contract was awarded to 1 supplier.

UNIVERSITY OF SOUTHAMPTON

Address

University of Southampton, University Road, Highfield, Southampton SO17 1BJ

Reference

None

Supplier is SME?

No

About the buyer

Contact name

NHSE Commercial

Address

133-155 Waterloo Rd
London
SE1 8UG
GB

Email

england.commercialqueries@nhs.net